This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove pfizer-brings-multiple-myeloma-battle-johnson-johnson-fda-approval-elrexfio
Remove Pharma Related Topics
Pharma Rep Pharma reps Biopharma Pharma sales reps Pharmaceutical manufacturing Pharmaceutical Sales Prescription Networking Pharmaceutical products Doctors More Related Topics >
article thumbnail

With FDA approval for Elrexfio, Pfizer brings multiple myeloma battle to Johnson & Johnson

Fierce Pharma

AUGUST 9, 2023

Another off-the-shelf, BCMA-directed drug has arrived for the treatment of multiple myeloma. Another off-the-shelf, BCMA-directed drug has arrived for the treatment of multiple myeloma. Pfizer's new Elrexfio will challenge Johnson & Johnson's entrenched position in the market.

FDA 217
FDA Marketing 217
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024